Quest Journals
Journal of Medical and Dental Science Research
Volume 10~ Issue 12 (2023) pp: 24-47
ISSN(Online) : 2394-076X ISSN (Print):2394-0751
www.questjournals.org

Research Paper

Characterizing Novel Antimicrobial Agents From Natural Sources To Combat Antibiotic- Resistant Bacteria

RUCHIRA DAN

ABSTRACT

Introduction*: The rapid emergence of antibiotic-resistant bacteria represents a critical global health concern, necessitating innovative solutions within the realm of antimicrobial drug discovery. In response, this thesis embarks on a comprehensive exploration of an alternative avenue for combating this escalating threat. By delving into the realm of natural sources, this research endeavors to unearth novel antimicrobial agents, thus addressing the formidable challenge of antibiotic-resistant bacteria head-on.The escalating threat of antibiotic-resistant bacteria has propelled the search for innovative solutions in the field of antimicrobial drug discovery. This research thesis endeavors to address this challenge through the comprehensive exploration of a dual strategy: integrating antibiotic-resistant sensitivity testing with the characterization of novel antimicrobial agents sourced from natural origins. By synergizing these approaches, the study seeks to provide insights into the potency of nature-derived compounds against antibiotic-resistant strains and their potential to revolutionize antibiotic therapies.*

Objectives*: The primary objective of this thesis is to investigate the potential of nature-derived compounds as a means to counteract the alarming surge in antibiotic resistance. The pivotal focus centers on the rigorous exploration of diverse natural sources, which encompass a plethora of plant species, marine organisms, fungi, and microorganisms. Through the strategic deployment of meticulous extraction, isolation, and characterization techniques, this study seeks to identify bioactive compounds that possess the potential to serve as potent treatments against recalcitrant multi-drug resistant pathogens.*

Methodology*: This research advances the current understanding of these newfound bioactive compounds by unraveling their intricate mechanisms of antimicrobial activity. Such insights are paramount in discerning their viability for clinical translation and application. By systematically investigating the interaction dynamics between these compounds and bacterial cells, this research endeavors to decipher the mechanisms that underlie their effectiveness against antibiotic-resistant strains. This deeper comprehension holds the key to their potential for circumventing existing resistance mechanisms, thus presenting a promising avenue for curbing the escalating rates of resistance.*

Findings*: The findings of this study significantly contribute to the larger discourse surrounding antimicrobial drug discovery and the ongoing struggle against antibiotic-resistant bacteria. The insights garnered from characterizing these novel agents gleaned from nature extend beyond their mere discovery. They offer a unique window into the broader landscape of drug development, highlighting the potency of compounds derived from natural sources as a crucial strategy in the relentless battle against antibiotic resistance.*

Conclusion*: In conclusion, this thesis underscores the imperative nature of nature-inspired drug discovery. It outlines a pathway that not only underscores the significance of harnessing the power of natural sources to address the challenge of antibiotic resistance but also illuminates the potential for transformative breakthroughs in combating this global healthcare crisis. Through systematic exploration and thorough characterization, this research stands as a testament to the resilience of scientific inquiry and its capacity to reshape the trajectory of healthcare.*

Keywords*: Antibiotic resistance, antimicrobial agents, sensitivity testing, natural sources, bacterial resistance, drug discovery, growth inhibition, resistance mechanisms, targeted therapies, mechanism of action studies, preclinical trials, clinical validation.*

R*eceived 145 Dec., 2023; **R****evised 26 Dec., 2023; **A****ccepted 29 Dec., 2023* © *The author(s) 2023.*
P*ublished with open access at **www.questjournals.org***

I. INTRODUCTION

1.1 Background:

Increased microorganism resistance to routinely used antibiotics has grown to be a significant problem in the contemporary environment. The widespread spread of bacteria resistant to antibiotics is a result of the widespread use of antimicrobial drugs in human and animal healthcare. The World Health Organisation (WHO) describes antibiotic resistance in microorganisms as a "major threat to public health" due to the danger it presents to national and international public health. Regular infections would no longer be able to be treated effectively due to the rising trend in antibiotic resistance, and procedures would become riskier and cost more to perform *(Teshome et al., 2020; Yang et al., 2008).*

The Antibiotic Era: A Triumph in Medicine:

The discovery of antibiotics in the 20th century ushered in a transformative era in medicine. These antimicrobial compounds revolutionized the treatment of bacterial infections and led to remarkable reductions in mortality rates associated with infectious diseases. From penicillin to tetracycline, antibiotics became indispensable tools in the arsenal of healthcare, providing a reliable means to combat a wide spectrum of bacterial pathogens.

The Unrelenting Challenge of Antibiotic Resistance:

However, the remarkable success of antibiotics was not without consequences. Over time, the adaptive nature of microorganisms led to the development of resistance mechanisms. Bacteria, driven by evolutionary pressures, acquired genetic alterations that rendered antibiotics less effective or entirely ineffective. This phenomenon, known as antibiotic resistance, has become an escalating global health crisis.

The Emergence of Multidrug-Resistant Bacteria:

Today, healthcare practitioners confront a new reality – the rise of multidrug-resistant bacteria. These formidable pathogens have acquired resistance to multiple classes of antibiotics, limiting the therapeutic options available to treat infections. In some cases, the emergence of pan-resistant strains, impervious to all known antibiotics, threatens to push us into a post-antibiotic era where once-treatable infections could become untreatable.

The Limitations of Conventional Antibiotics:

Conventional antibiotics, while highly effective when initially introduced, are losing their efficacy against resistant bacterial strains. The mechanisms of resistance include alterations in target sites, enzymatic inactivation of antibiotics, and the active efflux of drugs from bacterial cells. These defence mechanisms challenge the very foundation of our antibiotic-based approach to infection control.

The Global Health Imperative: Antibiotic Resistance

In the annals of medical history, the discovery and subsequent development of antibiotics marked a monumental triumph over infectious diseases. These wonder drugs revolutionized healthcare, offering a potent means to combat a wide array of bacterial infections. However, the efficacy of antibiotics, once considered invincible, is now under siege. The global healthcare community faces a formidable adversary: antibiotic-resistant bacteria. This contemporary scourge threatens to unravel decades of progress in modern medicine, rendering previously treatable infections increasingly recalcitrant and lethal. It is in this context that the urgent need for innovative solutions arises.

Antibiotic resistance in bacteria has been linked to a number of molecular pathways, including the following:

i) Resistance to mutation. In terms of target site change, decreased drug absorption, and activation of the efflux pump to release toxic chemicals, mutation offers resistance to antibiotics.

ii) Horizontal gene transfer of mobile antibiotic resistance genes via conjugative plasmids or transposons, which may enable survival at high antibiotic doses *(Zanotto et al., 2016).*

The Waning Arsenal of Conventional Antibiotics

Antibiotic resistance, a phenomenon driven by the evolutionary adaptability of microorganisms, challenges the very core of our approach to infection control. Bacteria, through mechanisms such as mutation, horizontal gene transfer, and efflux pumps, have honed their ability to evade the effects of antibiotics. These once-miraculous drugs, which served as stalwart defenders against infections ranging from minor ailments to life-threatening diseases, are now progressively succumbing to the insidious advance of resistance.

Turning to Nature's Pharmacy

In the face of this escalating health crisis, the gaze of scientists, researchers, and healthcare professionals turns toward the diverse and bountiful offerings of the natural world. Throughout human history, nature has consistently provided an abundant reservoir of inspiration and therapeutic agents. From traditional remedies rooted in plant extracts to the serendipitous discovery of penicillin, the natural world has been a reliable source of bioactive compounds with remarkable antimicrobial properties.

The Rich Tapestry of Nature-Derived Compounds

The array of natural sources is staggering in its diversity. It encompasses terrestrial flora, marine organisms, fungi, and microorganisms, each harboring unique compounds with the potential to become the next generation of antimicrobial agents. The intricate chemistry of these compounds, honed through evolution over millions of

years, presents an invaluable resource for researchers seeking novel solutions to the challenge of antibiotic resistance.

A Two-Pronged Approach: Characterization and Combat

This research thesis embarks on a dual mission, guided by the confluence of scientific curiosity and the urgency of real-world application. First and foremost, it endeavors to explore, isolate, and characterize novel antimicrobial agents sourced from nature. These compounds, extracted from the depths of rainforests, the expanse of oceans, and the heart of microbial communities, hold the promise of being the next frontier in antibiotic discovery.

The Crucial Battle Against Antibiotic Resistance

The second facet of this research is equally vital: the combat against antibiotic-resistant bacteria. As resistance mechanisms evolve and spread, it is imperative to assess the effectiveness of these novel compounds against resistant strains. The litmus test lies in their ability to counteract the sophisticated defences developed by bacteria, preserving our ability to treat infections effectively.

An Integrated Structure

This research thesis is structured to synthesize these two intertwined objectives. It is poised to traverse the realms of natural compound characterization, antimicrobial efficacy evaluation, mechanistic investigations, and the practical implications of these findings. As we embark on this scientific journey, we aim to not only expand the boundaries of knowledge in the field of antimicrobial drug discovery but also to contribute substantively to the ongoing fight against antibiotic resistance.

1.2 Antibiotic-Resistant Sensitivity Testing

Antibiotic sensitivity testing, also known as antibiotic susceptibility testing or AST, is a laboratory procedure used to determine the effectiveness of antibiotics against specific bacterial strains. The results of these tests guide clinicians in selecting the most appropriate antibiotics for treating bacterial infections. Here are the general steps involved in conducting antibiotic sensitivity testing:

1. Isolation and Identification of the Bacterial Strain:

- Obtain a pure culture of the bacterial strain causing the infection. This may involve collecting samples from the patient, streaking the sample onto agar plates, and incubating to obtain a pure colony.

2. Inoculation of Test Organisms:

- Select the bacterial strain(s) to be tested. Typically, clinical laboratories use standardized bacterial strains or reference strains for consistency.
- Prepare a bacterial suspension of the test organism(s) to a specific turbidity standard (usually equivalent to a 0.5 McFarland standard) to ensure uniformity in the test.

3. Preparation of Antibiotic Disks:

- Obtain antibiotic disks impregnated with specific concentrations of antibiotics. These disks are commercially available and standardized for sensitivity testing.

4. Inoculation of Mueller-Hinton Agar Plates:

- Using a sterile cotton swab or loop, evenly spread the bacterial suspension onto Mueller-Hinton agar plates. The thickness of the bacterial lawn should be uniform.

5. Placing Antibiotic Disks:

- Place the antibiotic disks on the inoculated agar plates. The selection of antibiotics should be based on the suspected or known pathogens and the clinical context.
- Space the disks evenly across the plate to ensure accurate results.

6. Incubation:

- Incubate the plates at the appropriate temperature (usually 35-37°C) for a specific period (typically 16-18 hours).

7. Measurement of Zones of Inhibition:

- After incubation, examine the plates. Clear zones around the antibiotic disks (zones of inhibition) indicate that the antibiotic has effectively inhibited bacterial growth.
- Measure the diameter of each zone of inhibition in millimeters using a caliper or ruler.

8. Interpretation of Results:

- Compare the measured zone diameters with standardized interpretative guidelines provided by organizations like the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
- Results are typically categorized as "Susceptible," "Intermediate," or "Resistant" based on the zone diameter and the specific breakpoints for each antibiotic-bacterium combination.

9. Reporting:

- Generate a report summarizing the susceptibility or resistance of the bacterial strain to each tested antibiotic. This report is sent to the clinician to guide antibiotic therapy.

10. Quality Control:

- Regularly perform quality control checks to ensure the accuracy and reliability of the antibiotic sensitivity testing process. This involves using known bacterial strains with established sensitivity patterns.

11. Clinical Correlation:

- The final step involves the clinician's interpretation of the laboratory results in the context of the patient's clinical condition and medical history. The choice of antibiotic therapy is based on both the susceptibility test results and clinical judgment.



Figure1:Antibiotic susceptibility testing (AST) by KIRBY BAUER

1.3 Research Objectives and Hypotheses

The primary objective of this research is to characterize novel antimicrobial agents sourced from nature and assess their potential to combat antibiotic-resistant bacteria. This investigation will involve the identification and isolation of bioactive compounds, followed by comprehensive structural and functional characterization. Through a combination of in vitro assays, mechanistic studies, and potential synergistic evaluations with existing antibiotics, the research aims to elucidate the effectiveness of these novel agents against antibiotic-resistant strains.This research thesis centers on the integration of two distinct yet synergistic approaches: **antibiotic-resistant sensitivity testing** and the **characterization of novel antimicrobial agents from natural sources**. The primary focus lies in unveiling the potency of these compounds against antibiotic-resistant bacterial strains. By employing antibiotic-resistant sensitivity testing, the study aims to evaluate the effectiveness of these agents in inhibiting the growth of resistant bacteria, thereby contributing to the development of innovative therapeutic strategies.

The hypotheses driving this study are:

- Natural sources harbor untapped reservoirs of bioactive compounds with potent antimicrobial properties.
- The characterized novel antimicrobial agents will demonstrate efficacy against antibiotic-resistant bacteria.
- Exploring the mechanisms of action of these compounds will provide insights into their potential to circumvent resistance mechanisms.

II. LITERATURE REVIEW

The escalating threat of antibiotic-resistant bacteria has become a global public health concern. The overuse and misuse of antibiotics have led to the development of multidrug-resistant bacterial strains, posing significant challenges in the treatment of infectious diseases *(Laxminarayan et al., 2013).*

Nature as a Reservoir of Novel Antimicrobials

- **Plant-Derived Compounds**

Throughout history, traditional medicine has drawn upon the antimicrobial properties of plants. Recent research has uncovered numerous novel antimicrobial compounds from plants. For example, the plant Allicin, found in garlic, has shown potent antibacterial activity against various drug-resistant strains *(Yun et al., 2014).*

The potential of plants as sources of novel antimicrobial agents continues to be a subject of extensive research. Traditional remedies have long exploited the antibacterial properties of plant extracts. Recent studies have identified various active compounds with significant antimicrobial potential. For example, the compound berberine, extracted from the berberis plant, exhibits antibacterial activity against a range of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) *(Xu et al., 2018).* The diversity of plant-derived compounds offers a broad spectrum of antimicrobial options.

- **Microbial Sources**

Microorganisms, including bacteria and fungi, have historically been prolific producers of antibiotics. The discovery of penicillin from the fungus Penicillium marked a groundbreaking advancement. In recent years, investigations into microbial communities from diverse environments have revealed new compounds with promising antimicrobial *properties (Munita and Arias, 2016).*

Microorganisms, especially bacteria and fungi, have historically been prolific sources of antibiotics. The bacterium Streptomyces, for instance, has given rise to numerous antibiotics, including streptomycin and tetracycline. Modern microbial exploration continues to unveil novel compounds with remarkable antimicrobial properties (Bérdy, 2012). For example, teixobactin, isolated from a soil bacterium, holds promise as a potent antibiotic capable of targeting multidrug-resistant strains *(Ling et al., 2015).*

- **Marine-Derived Compounds**

Marine ecosystems, covering a substantial portion of the Earth's surface, offer a vast reservoir of bioactive compounds. Marine organisms, adapted to extreme conditions, produce unique molecules as a defence mechanism. For instance, compounds extracted from marine sponges have demonstrated significant antimicrobial activity, particularly against drug-resistant strains *(Mayer et al., 2007).*

The vast marine environment, characterized by extreme conditions and biodiversity, has become a focal point for drug discovery. Marine organisms, such as sponges, corals, and algae, produce bioactive compounds as part of their defense mechanisms against microbial threats. These marine natural products have demonstrated significant antimicrobial activity against both drug-susceptible and resistant bacteria *(Penesyan et al., 2010).* Notably, compounds like lugdunin, derived from a marine bacterium, exhibit potent antibacterial properties and may hold the key to combating drug-resistant infections *(Zipperer et al., 2016).*

The Earth's oceans, which cover over 70% of the planet's surface, are teeming with biodiversity. This unique environment, characterized by extreme conditions and rich ecosystems, has emerged as a promising source of novel antimicrobial compounds. The marine world harbors organisms like sponges, corals, and microorganisms that have evolved intricate defense mechanisms, including the production of bioactive compounds. Such compounds are now the focus of intensive research efforts *(Faulkner, 2002).* For example, compounds like Discodermolide, isolated from deep-sea sponges, have demonstrated potent antibacterial activity against drug-resistant strains *(Gunasekera et al., 2003).*

Unique Mechanisms of Action

One of the distinguishing features of many nature-derived antimicrobials is their unique mechanisms of action. For example, certain marine-derived compounds disrupt bacterial biofilms, preventing the formation of resistant communities *(Romero et al., 2013).*

One of the captivating features of nature-derived antimicrobials is their ability to employ distinctive mechanisms of action. For example, certain marine-derived compounds disrupt bacterial biofilms, a collective mode of growth that enhances bacterial resistance and virulence. Such compounds can hinder biofilm formation and weaken the resilience of drug-resistant bacterial communities *(Hentzer et al., 2002).*

Overcoming Resistance Mechanisms

Traditional antibiotics can become ineffective as bacteria develop resistance through mutations, horizontal gene transfer, and efflux pumps. Nature-derived compounds may offer a solution by targeting bacteria through multiple pathways simultaneously, making it more difficult for them to adapt and develop resistance *(Wright, 2019).*

A recurring challenge in antimicrobial therapy is the ability of bacteria to develop resistance through various mechanisms. Nature-derived compounds may provide a solution by targeting bacteria through multiple pathways, making it arduous for them to adapt and develop resistance. This multifaceted attack strategy can potentially circumvent or mitigate resistance development *(Davies and Davies, 2010).*

Understanding the mechanisms of action of nature-derived antimicrobials is paramount. For example, some marine natural products, like prodigiosin, disrupt bacterial cell membranes, leading to cell lysis and death *(Darshan and Manonmani, 2015).* Others, like curcumin from the turmeric plant, inhibit bacterial DNA gyrase, a crucial enzyme in DNA replication *(Tyagiet al., 2015).* Such diversity in mechanisms of action offers opportunities for combination therapies and can potentially combat resistance on multiple fronts.

Microbial Resistance and Natural Solutions

The relentless evolution of resistance mechanisms in bacteria poses a formidable challenge. However, nature-derived compounds have shown promise in addressing this issue. Compounds like quorum sensing inhibitors (QSIs), derived from both plants and marine sources, interfere with bacterial communication systems, reducing their virulence and ability to form biofilms *(Rasmussen et al., 2005).* Such compounds may not only serve as direct antimicrobials but also as tools to attenuate resistance development.

Harnessing Microbial Diversity

Microorganisms, particularly those residing in diverse ecosystems such as soils and hot springs, continue to be prolific sources of antibiotics. Streptomyces species, known for their prolific production of antibiotics, remain essential in this pursuit *(Hopwood, 2007).* Recent exploration of extreme environments has led to the discovery of novel compounds with antimicrobial potential. For instance, compounds like abyssomicins, isolated from deep-sea actinomycete bacteria, exhibit unique structures and mechanisms of action, challenging resistant bacteria *(Carr et al., 2019).*

Exploring Unique Mechanisms of Action

One of the remarkable aspects of nature-derived antimicrobials is their ability to employ diverse mechanisms of action. Some marine compounds, such as pederin from beetles, disrupt protein synthesis in bacterial cells by binding to ribosomes *(Frohlich et al., 2000).* Others, like nisin, a bacteriocin produced by lactic acid bacteria, disrupt bacterial cell membranes *(Heng et al., 2007).* This diversity in mechanisms of action can offer innovative avenues for combatting resistant bacteria.

Clinical Implications and Challenges

While the potential of nature-derived antimicrobials is promising, several challenges remain. Rigorous validation, optimization of compound efficacy, and addressing issues of toxicity are critical steps in the development process. Furthermore, the regulatory pathway for natural products can be complex and time-consuming.

While the promise of nature-derived antimicrobials is evident, translating these compounds into clinically viable treatments presents challenges. Rigorous testing, optimization of compound efficacy, and addressing issues of toxicity are essential steps in the development process. Additionally, regulatory approval and large-scale production for clinical use require substantial resources and time.

Clinical Implications

- **Combating Multidrug-Resistant Pathogens**

The urgent need for novel antimicrobial agents is underscored by the alarming rise of multidrug-resistant pathogens. Traditional antibiotics are increasingly rendered ineffective against these formidable foes, leading to prolonged illnesses, higher mortality rates, and increased healthcare costs *(Tacconelli et al., 2018).* Nature-derived antimicrobials offer a glimmer of hope in addressing this crisis.

- **Synergy with Conventional Antibiotics**

One of the promising aspects of nature-derived compounds is their potential to work synergistically with existing antibiotics. Combination therapies can enhance the efficacy of conventional drugs while potentially reducing the risk of resistance development. This approach has been explored in several studies, demonstrating the potential of novel compounds to revitalize the effectiveness of older antibiotics *(Ocampo et al., 2014).*

Challenges and Future Directions

- **Validation and Optimization**

The journey from discovery to clinical application of nature-derived antimicrobials is fraught with challenges. Rigorous validation through preclinical and clinical trials is essential to establish safety and efficacy. Furthermore, optimization of compound formulations and dosages is required to maximize their therapeutic potential *(Projan and Shlaes, 2004).*

- **Regulatory Hurdles**

Navigating the regulatory landscape for natural products can be intricate. Regulatory agencies require robust evidence of safety and efficacy before approving new therapies. Consequently, extensive testing and documentation are imperative for successful regulatory submissions *(Sharma and Pinnaka, 2019).*

- **Large-Scale Production**

Scaling up the production of nature-derived antimicrobials for clinical use is a complex endeavor. Challenges include ensuring consistent compound yields, minimizing environmental impact, and meeting the demand for large quantities of therapeutic agents *(Yadav et al., 2019).*

Future Directions

- **Precision Medicine**

The era of precision medicine holds significant promise for the development of nature-derived antimicrobials. Tailoring treatments based on individual patient profiles, including genetic and microbiome factors, may enhance treatment outcomes and reduce the risk of *resistance (Thaden et al., 2016).*

- **Novel Drug Delivery Systems**

Incorporating innovative drug delivery systems, such as nanoparticles and liposomes, can enhance the targeted delivery of nature-derived antimicrobials. These technologies can improve drug bioavailability, reduce side effects, and increase therapeutic efficacy *(Talekar et al., 2014).*

Conclusion

In conclusion, the exploration of novel antimicrobial agents from natural sources holds great promise in the fight against antibiotic-resistant bacteria. The rich biodiversity of the marine environment, coupled with the prolific production of antibiotics by microorganisms, offers a treasure trove of compounds with unique mechanisms of action. These compounds may hold the key to overcoming bacterial resistance mechanisms. However, the translation of these discoveries into clinical applications is a complex journey that requires careful validation and development.

In conclusion, characterizing novel antimicrobial agents from natural sources to combat antibiotic-resistant bacteria represents a beacon of hope in the battle against multidrug-resistant pathogens. These compounds offer the potential to revitalize antibiotic therapy, either through direct antimicrobial activity, synergy with existing drugs, or by countering resistance mechanisms. However, the journey from discovery to clinical application is arduous, demanding rigorous validation, regulatory adherence, and large-scale production. Despite these challenges, the continued exploration of nature-derived antimicrobials, coupled with precision medicine and innovative drug delivery systems, provides a promising roadmap for the future of antimicrobial therapy.

III. METHODOLOGY

3.1 Sample Collection and Preparation

For this research, an extensive and diverse array of natural sources will be meticulously collected to ensure the comprehensive exploration of antimicrobial agents. This will encompass:

- **Plant Samples**: Plants will be sourced from ecologically diverse regions, spanning various climates and ecosystems, to capture a wide range of phytochemicals.
- **Marine Samples:** Marine samples will be obtained through sustainable practices, adhering to conservation guidelines, and encompassing a variety of oceanic regions to harness the rich biodiversity of marine organisms.
- **Bacterial Strains:** A broad selection of bacterial strains, will be chosen for their clinical relevance and resistance profiles. These strains will include a diverse spectrum of pathogens, both Gram-positive and Gram-negative, to represent a comprehensive array of microbial threats.

All collected samples, whether botanical, marine, or bacterial, will undergo a rigorous cleaning, processing, and preservation process. These preparations will strictly follow established protocols to maintain sample integrity and to ensure the optimal retention of bioactive compounds.

3.2 Extraction and Isolation

To access the vast array of bioactive compounds within the collected samples, various extraction techniques tailored to the specific nature of each source will be employed. These techniques will yield crude extracts rich in potentially active molecules from all total samples.

Following extraction, the crude extracts will undergo meticulous purification using methods such as liquid-liquid extraction and solid-phase extraction. These purification steps will separate compounds based on their chemical properties, resulting in fractions with high purity. The outcome will be a substantial collection of purified fractions, one from each of the total samples.

The resulting fractions will then be subjected to bioactivity-guided isolation techniques, allowing for the identification of compounds with potent antimicrobial activity from each sample.

3.3 Bioassays and Screening

The effectiveness of the isolated compounds will be rigorously evaluated using standardized bioassays. This will involve a comprehensive panel of clinically relevant bacterial strains, including both susceptible and resistant isolates. These strains have been meticulously chosen to represent the full spectrum of microbial threats.

Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values will be determined for each of the total samples, quantifying the potency of the isolated compounds. The extensive dataset generated by these assays will be crucial for subsequent investigations.

3.4 Structural Characterization

For compounds demonstrating significant antimicrobial activity, structural characterization is paramount. Advanced techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry will be employed to elucidate the chemical structures of the active compounds.

This process will be conducted for each of the samples, allowing for precise identification and confirmation of the chemical structures of the active antimicrobial agents.

3.5 Antibiotic-Resistant Sensitivity Testing

To assess the sensitivity of bacterial strains to antibiotics, a standardized testing process will be employed. The total selected bacterial strains will be exposed to a panel of antibiotics, including commonly used clinical antibiotics.

Growth responses will be continuously monitored, and zones of inhibition will be meticulously measured for each of the total strains. These results will provide a comprehensive understanding of the effectiveness of antibiotics against each bacterial strain, offering insights into the extent of antibiotic resistance.

- **SENSITIVITY ANALYSIS:** Also known as susceptibility testing, sensitivity analysis aids medical professionals in identifying the most potent antibiotic to eradicate an infectious microbe. A test to ascertain a bacteria's "sensitivity" to an antibiotic is known as a sensitivity analysis. It also affects the antibiotics' capacity to eradicate the bacterium. Susceptibility testing is a tool used by doctors to choose the best antibiotic therapy for an infectious condition and track changes in bacterial resistance to antibiotics.

Purpose of sensitivity analysis:

Common antibiotics are ineffective against a lot of germs. This indicates that the bacteria cannot be killed by the antibiotic. Sensitivity analysis is a great tool for swiftly identifying whether bacteria are resistant to particular medicines or medications.

Steps used during sensitivity analysis:

A bacterial sample is the first step in sensitivity analysis. This sample will be obtained by doctors sampling the affected region. Samples can be drawn from things including blood, urine, and sputum (spit). The sample will be sent to a lab where it will be spread out on a sturdy growth surface, where the bacteria will develop and proliferate. The bacteria will aggregate into colonies, or sizable collections of bacteria, and each colony will be subjected to several antibiotics. In response to the antibiotics, these colonies may be sensitive, resistant, or intermediate:

When bacteria are susceptible, it suggests the antibiotic is working since they are unable to proliferate in the presence of the medication. While bacteria are resistant, they might develop even while an antibiotic is present. This indicates that the antibiotic is ineffective.

According to *Martinez et al. (2020),* intermediate signifies a greater dose of the medication is required to stop the growth of the bacteria.

Methods for evaluating the susceptibility of microbes

Respect should be given to the following prerequisites:

i) From the given sample, AST bacteria must be isolated in pure culture.

ii) As established reference techniques should be employed for identification, the tested bacteria are consistently and accurately identified to the genus and/or species level.

iii) For further examination, bacteria isolates deemed to be the most significant should be preserved at 70 to 80 degrees Celsius along with a sample of other isolates.

The following variables affect AST techniques:

i) The ideal inoculant concentration must be established after the bacteria has been isolated in pure culture in order to get reliable susceptibility data. For AST testing, bacteria or other organisms should come from a fresh culture,

ii) How the agar and broth media were made and what was in them (such as the pH, if they were supplemented, whether they included cations, thymidine, or thymine). As well as determining and documenting the applied processes, performance and sterility testing of media batches should be conducted.

iii) The antimicrobial content of the carrier (antibiotics used in microtiter plates, discs, strips, and tablets); iv) The composition of the solvent and diluent used to prepare antimicrobial stock solutions;v) The conditions of growth and incubation (time, temperature, atmosphere, e.g. CO2), vi) Agar depth, vii) Number of concentrations tested per agar and broth dilution, viii) The test controls to be used, including the reference organisms used.ix) The subsequent interpretive criteria (clinical breakpoints, epidemiological cut-off values).

The following variables may be taken into consideration while choosing an AST methodology:
Easy performance, flexibility, adaptability to automated or semi-automated systems, cost, reproducibility, reliability, accuracy, interest-related antimicrobials and organisms in that specific OIE Member, and availability of suitable validation data for the range of organisms to be susceptibility tested are all factors.

Methods for phenotypic AST:
1. Diffusion: The gold standard approach for determining a bacteria's susceptibility is disc diffusion. *In 1956, Bauer and Kirby* conducted tests to develop it after completing all areas of optimisation by modifying the physical environment. This technique involves suspending the patient-isolated bacterial sample into growth media and standardising it using a turbidity test. The antibiotic-treated paper is then tapped on the inoculated plate after the suspension has been dispersed onto the MH agar plate that has hardened. After an overnight incubation at 35 °C, the inhibition zone forms as the antibiotic-containing disc diffuses through the agar. The size of the inhibition zone correlates to the antibiotic concentration, and the diameter of the clearing zone surrounding the disc is measured *(Zeeshan et al., 2019).* A commercially available chromogenic disc technique *(Cefinase; Becton Dickinson Microbiology Systems, Cockeysville, Maryland)* is used to quickly identify the generation of -lactamases in Staphylococcus species and Haemophilus influenza *(Cockerill et al., 2017).*
Diffusion technique history: Several diffusion-based studies were conducted before the widely used disc diffusion approach. The first technique for analysing antibiotics was Fleming's gutter method, which he established in 1920. In this technique, an antibiotic was discharged into a gutter built on solid agar, which enabled the antibiotics to permeate through it. The "Oxford cup method" was later created by Abraham et al. 1941 as a variation to this concept. For dispersion, a glass cup was used in place of the gutter in this manner. Pope in 1940, Foster and Woodruff in 1943, and Vincet in 1944 all employed a paper disc loaded with antibiotics to diffuse the medication at the same time. Because of their complexity in handling, labor-intensive operation, sterilisation, and evaporation, these approaches were limited by imprecise analysis. Penicillin was the sole antibiotic used for susceptibility testing, but as the number of dangerous infections increased, the development of efficient medicines and practical susceptibility testing methods took precedence. As a result, modifications to the technique have been created to increase its adaptability and usefulness. Separately, penicillin pills and the conventional 6.5-mm disc technique were created in *1947 by Hoyt, Levine, and Bondi*. Gould and *Bowie (1952) and Stokes (1955)* made it possible to distinguish between susceptible and resistant bacteria using the multiple disc diffusion approach. Due to differences in findings acquired from various labs, all of these approaches were erroneous, unreliable, and inappropriate for regular testing. Later, in 1966, the disc diffusion method developed by Bauer and Kirby was approved as the industry standard for susceptibility testing. For regular susceptibility testing in clinical laboratories, this approach is highly helpful *(Zeeshan et al., 2019, Wheat, 2001).*
Benefits include the ease with which test antimicrobial discs may be modified as necessary and the ability to utilise the test as a screening test for a large number of isolates. i)Easy modification of test antimicrobial discs as necessary ii) Capable of identifying a selection of isolates for further testing using other techniques, such as MIC determination iii) Low price.
It does, however, have some important disadvantages in addition to these benefits: A lack of data for several bacteria (Pseudomonas, Bacillus, and Corynebacterium strains) It performs poorly when analysing slow-growing and fastidious bacteria (Zeeshan et al., 2019) and only semi-automation is provided (Sirscan).
2. Dilution: Starting in the early 1870s, dilution was one of the initial techniques used in microbiological practise. It permits bacterial identification and growth while in suspension. The two fundamental forms of dilution are microdilution and microdilution, with broth and agar serving as the most popular media (Zeeshan et al., 2019). The goal of the broth and agar dilution procedures is to identify the tested antibiotic at the lowest dose necessary to prevent bacterial growth (CLSI, 2006).
Background of Dilution: The founders of the science of bacteriology were named as Pasteur, Lister, Koch, and Ehrlich. They experimented with the idea of macro-dilution. The macro-dilution technique was improved by William Roberts and John Tyndall, who also observed bacterial growth in a diluted solution. Several scientists developed the serial dilution method in the beginning of the 20th century. They defined the dilution factor in terms of geometric progression and constructed the generalised mathematical equation for evaluating the dilution findings *(Zeeshan et al., 2019).* Alexander Fleming used the serial dilution technique in 1929 to better understand how antibiotics work. In this procedure, antibiotics are mixed in two-fold dilutions with a liquid medium that has already been inoculated in order to assess the turbidity and identify the antibiotic activities. Fleming revised the earlier method in 1942, using pH rather than turbidity to detect antibiotic activity. The "tube dilution method" or broth macro dilution, which is regarded as the standardised dilution method for both minimum inhibitory concentration (MIC) and AST, was established by Rammelkamp and Maxon in the same year. Schmith and Reymann made the first effort at AST in the 1940s using an agar *medium (Wheat, 2001).*
Broth dilution is a technique in which various antibiotic concentrations are prepared, dispensed into micro-centrifuge tubes containing bacterial growth medium (typically serial two-fold dilutions), and then the final

volume is made up by adding the medium and incubated overnight at 35 °C *(Zeeshan et al., 2019, Stephanie et al., 2010).* According to Puttaswamy et al. (2018), CLSI (2006), the broth dilution method can be used with either larger quantities (macrodilution) in tubes with a capacity of 1 ml or more, or smaller volumes (microdilution) using microtitration plates. The cost of purchasing antimicrobial plates and related equipment, along with the fact that this methodology is less adaptable to changing needs of the surveillance/observing programme than disc diffusion or agar dilution, may prevent some laboratories from using it *(Puttaswamy et al., 2018).*



Figure 2: Broth dilution method

The antibiotic to be tested against a specific strain of bacteria is directly added into the agar medium using the well-known technique known as agar dilution *(Wheat, 2001).*

Agar dilution methods have the following benefits: i) The capacity to test multiple bacteria, excluding bacteria that swarm, on the same set of agar plates simultaneously; ii) The potential to enhance the identification of MIC endpoints and expand the range of antibiotic concentration; and iii) The capacity to semi-automate the technique by using an inoculum-replicating apparatus. There are inoculum replicators that can transmit between 32 and 60 distinct bacterial inoculates to each agar plate that are commercially made.

Agar dilution techniques have a few other downsides as well:

The plates should typically be used within a week (or less, depending on the antimicrobials tested) of being prepared, but this can vary depending on the antimicrobials tested. The endpoints are not always easy to read, and it can be difficult to verify the purity of the inoculum.

Figure 3: Agar Dilution test(*Athamanolap et al., 2017)*

3. **E-test:** Epsilometer test is one of the commonly used gradient diffusion methods developed by Bolmstrom and Eriksson in 1980, where a plastic strip impregnated with gradually decreasing concentrations of a given antibiotic which is placed on the solid surface of an agar plate preinoculated with bacteria to be tested. The strip has an interpretive scale on the back side, which aids in reading the zone of inhibition. The plates are incubated for overnight, at the end of which the inhibition zone is identified and the corresponding MIC value is determined. The MIC is interpreted as a point on the scale where the inhibition zone intersects the strip. This method can be used to test the effect of multiple antibiotics on a single platform, when placed at sufficient distance from each other to prevent inhibition zone overlaps*(Zeeshan et al., 2019, Puttaswamy et al., 2018).*

E-test is appropriate and convenient for Food and Drug Administration (FDA) for it's simplicity, accuracy and reliability. In clinical laboratories E-test is a preferential method over standardized disk diffusion and dilution techniques, because the ability of convenient interpretations of MIC under diverse physical conditions *(Wheat, 2001).*

In the 1990s, series of comparative studies with the other standardized techniques, established the significance of the Etest. Many strains of *Neisseria gonorrhoeae, Helicobacter pylori* and several other clinical isolates were tested by Etest and contrasted with standard methods, resulting in a good correlation in the range of 91%–99%. Recently, in 2016, methicillin-sensitive *Staphylococcus aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA) isolates were examined with an Etest to determine the MIC of ceftaroline and the results were compared with broth microdilution (BMD) which showed an excellent agreement of more than 95%. Multiple cultures of *Campylobacter spp*. against seven antibiotics were also examined by Etest to determine their resistance. One of the major advantages of the Etest is its sensitivity; it can identify extended-spectrum β-lactamase (ESBL). Besides several advantages, there are certain drawbacks: primarily related to the inaccurate and inconsistent behaviour of the Etest for certain antibacterial agents, such as Penicillin, ciprofloxacin, ofloxacin, and rifampicin. Some other disadvantages such as pH-sensitive coated antibiotics, strip storage, laboratory set-up for proper plate inoculation and incubation, expensive batch performance, makes the Etest complicated for routine test analysis *(Zeeshan et al., 2019).*



Figure 4: E-test (*Athamanolap et al., 2017)*

4. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS): MALDI-TOF MS, is another sensitive method for bacterial identification, introduced in 2000. It is a useful method for clinical relevance because of its high sensitivity and accuracy. Several studies have been done which disclose its significance in differentiating MRSA, MSSA, and other bacterial strains where susceptible and resistant bacteria have been evaluated through spectral peak analysis. The efficiency of MALDI-TOF MS has been further investigated on vancomycin-resistant Enterococci, where more than 90% sensitivity has been recorded. The newly developed MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA) is a more-straightforward and cost-effective inflection of MALDI-TOF MS used for both AST and MIC determination. Among all the advantages, the expensive nature of the instrument and its maintenance are prime disadvantages for mass application *(Zeeshan et al., 2019).*

Antimicrobial Susceptibility Testing of *Neisseria gonorrhoeae* in Canada :

Neisseria gonorrhoeae is the bacterial agent causing gonorrhea infections. In Canada it is the second most commonly reported bacterial pathogen with more than 13,000 reported cases in 2013. Worldwide, the number of cases is considered to be 106 million. *N.gonorrhoeae* has developed resistance to all classes of the antimicrobials used for treatment, such as- sulfonamides, penicillins, tetracyclines and fluoroquinolones, so this is a serious concern. More recently, isolates with resistance to azithromycin and third generation cephalosporins have emerged. To control the spread and impact of antimicrobial resistance in *N. gonorrhoeae*, the WHO published a global action plan in 2012. The recommendations included increasing surveillance programs and strengthening laboratory capacity. Quality assurance (QA) systems are pivotal to certifying that the antimicrobial susceptibility data generated are accurate, standardized, and comparable nationally and internationally.Since 1985 the National Microbiology Laboratory (NML) of the Public Health Agency of Canada has observed antimicrobial susceptibilities in *N. gonorrhoeae* isolates as part of the National *Neisseria gonorrhoeae* Antimicrobial Surveillance Program. The NML offers a proficiency testing program to standardize the susceptibility testing data and to maintain the comparability of data generated from each province. Correct results lead to effective treatment options and improved public health prevention programs.

This report presents a collection of data through the Canadian National Gonococcal Antimicrobial Susceptibility Comparison Program from 2003 to 2012 (25 panels), where each panel typically included 4 *N. gonorrhoeae* isolates presently circulating in Canada and 1 blinded reference strain. Each participating laboratory tested the isolates with the agar dilution or Etest methods and antimicrobials that are routinely employed in their laboratory. All isolates are tested also in the NML.

The laboratories participating in this quality program from 2003 to 2012 reached an overall average agreement between participants' MIC results and modal MICs of more than 90%, which is considered the acceptable standard; only 1 laboratory had less than 90%. Concordance between the interpretations of the participant and the modal interpretations was more than 90% for all but only 2 laboratories had less than 90%. Table 1 represents the performance of the laboratories participating in the program in between 2003-2012.

Table 1: Performance of participating laboratories in the National Gonococcal Antimicrobial Susceptibility Comparison Program between 2003-2012.

Laboratory Code	No. of panels completed	Test Method Used	Antibiotics Tested[a]								Percent Agreement between MICs of Participant and modal MICs		Percent Concordance between Interpretations of Participant and modal Interpretations	
			Pen	Spec	Tet	Cx	Cip	Ce	Azi	Ery				
1	25	Agar Dilution	X		X	X	X				97.52%	(354/363)	98.13%	(367/374)
2	20 (2003-2012)	Agar Dilution	X	X	X	X	X	X	X	X	90.73%	(499/550)	91.80%	(593/646)
3	25	Agar Diln (9 panels)/Etest (19 panels)	X	X	X	X	X	X	X	X	96.15%	(749/779)	95.03%	(917/965)
4	25	Etest	X	X	X	X	X	X	X		97.99%	(536/547)	94.86%	(701/739)
5	25	Etest	X		X	X	X	X	X		96.78%	(542/559)	93.42%	(696/745)
6	25	Agar Dilution	X	X	X	X	X	X	X	X	95.44%	(272/285)	96.26%	(720/748)
7	25	Etest	X	X	X	X	X	X	X	X	94.29%	(694/736)	89.19%	(751/842)
8	18 (2004-2012)	Etest	X		X	X	X	X	X		98.77%	(400/405)	95.87%	(511/533)
9	14 (2005-2011)	Agar Diln (9 panels)/Etest (5 panels)	X	X	X	X	X				85.62%	(250/292)	85.71%	(294/343)
10[b]	25	Agar Diln (25 panels)/Etest (14 panels)	X	X	X	X	X	X	X	X	96.00%	(1272/1325)	95.63%	(1138/1190)

[a]A lowercase "x" indicates that the antibiotic was not tested for all panels. PEN, penicillin; SPEC, spectinomycin; TET, tetracycline; CX, ceftriaxone; CIP, cefixime; AZI, azithromycin; ERY, erythromycin.

[b]Laboratory 10 is the NML, which started using the Etest in addition to agar dilution in 2006.

The MICs and interpretations are compared to their modes for each antibiotic in Table 2. The percentages of agreement between the MIC results and their modes for each of the antibiotics were all more than 90%. This is also true for the proportion of agreement between interpretations for all of the antibiotics except tetracycline, partially due to the high percentage of tetracycline modal MICs at interpretative breakpoints. It is important to note that, for all antibiotics combined there were ≤1.5% false susceptible interpretations.

Table 2: MIC and categorical interpretation agreement among participating laboratories for each antibiotic

Antibiotic	Total no. of isolates	Total no. pairwise comparisons	Modal MIC range (mg/L)	Percentage of participant MICs that differ from the modal MICs by the following number of two-fold dilutions					% Agreement (no. of comparisons with concordant results/total no. of comparisons) by:		Modal MICs at Categorical Interpretation Breakpoints	
				≤-2	-1	Same	1	≥2	Modal MIC (±1 $\log_2$)	Categorical interpretation	Percentage	Number
Penicillin	106	838	0.016 - 64	4.1%	15.9%	66.0%	11.9%	2.2%	93.79% (786/838)	93.32% (1006/1078)	38.67%	41/106
Tetracycline	107	880	0.125 - 64	3.8%	19.1%	56.6%	16.5%	4.4%	91.82% (808/880)	84.23% (871/1034)	67.29%	72/107
Erythromycin	103	434	0.063 - 32	3.5%	13.4%	68.7%	12.7%	1.8%	94.70% (411/434)	90.89% (549/604)	50.49%	52/103
Spectinomycin	112	571	8 - 32	1.2%	11.0%	70.4%	16.1%	1.2%	97.55% (557/571)	98.67% (744/754)	0.00%	0/112
Ceftriaxone	117	978	0.0005 - 0.25	3.6%	17.7%	63.2%	14.1%	1.4%	94.99% (929/978)	96.07% (1027/1069)	23.93%	28/117
Ciprofloxacin	102	817	0.002 - 16	2.9%	15.7%	63.7%	14.9%	2.8%	94.25% (770/817)	94.48% (1129/1195)	23.53%	24/102
Cefixime	102	528	0.002 - 0.5	1.3%	15.2%	71.8%	10.2%	15.2%	97.16% (513/528)	98.10% (927/945)	11.76%	12/102
Azithromycin	105	779	0.032 - 16	1.5%	16.3%	68.8%	13.0%	0.4%	98.07% (764/779)	96.16% (877/912)	22.85%	24/105

Table 3: represents the agreement between agar dilution and the Etest for the test isolates of the panels of this study. For each isolate/antibiotic combination, the agar dilution modal MICs and Etest modal MICs as well as their interpretations were calculated separately for comparison. The modal MICs for the agar dilution and Etest methods were considered in agreement if they were within one 2-fold dilution of each other. For all of the antibiotics except tetracyclin, the percentage of agreements between the agar dilution and the Etest modal MICs were more than 90%. For tetracycline, ceftriaxone, and cefixime, the differences between the means of the agar dilution modal MICs and the Etest modal MICs were significant ($P< 0.05$), according to the matched-pair *t* test. For each of the antibiotics except tetracycline and erythromycin, the percent concordances between the Etest and agar dilution modal interpretations were more than 90%. More than 50% of the Etest MICs for tetracycline and erythromycin were 1 dilution lower than the agar dilution MICs. Due to the high proportion of modal MICs at interpretation breakpoints, the interpretation agreements were reduced.

Antibiotic	No. of isolates[a]	No. of Results Agar / Etest[b]	Percentage of Isolates (agar dilution modal MIC minus Etest modal MIC)					Percent Agreement of modal MICs	Matched Pair T-test, p<0.05 of modal MIC means			Percent Concordance of Interpretations	Modal MICs at Categorical Interpretation Breakpoints[c]	
			≤ -2 diln	-1 diln	same	+1 diln	≥+2 diln		t-value	p-value	significant		Percentage	Number
Penicillin	74	400 / 554	4.1%	35.1%	55.4%	5.4%	0.0%	96.0%	1.96	0.09525	no	94.5%	43.6%	34/78
Tetracycline	82	433/ 586	15.9%	69.5%	13.4%	1.2%	0.0%	84.1%	5.20	<0.00001	yes	79.3%	67.9%	57/84
Erythromycin	30	252 / 260	0.0%	56.7%	40.0%	3.3%	0.0%	100.0%	-0.45	0.65312	no	69.6%	73.3%	22/30
Spectinomycin	66	324/ 314	3.0%	42.4%	53.0%	1.5%	0.0%	97.0%	-0.15	0.87878	no	100.0%	34.8%	23/66
Ceftriaxone	90	398 /641	3.3%	35.6%	52.2%	8.9%	0.0%	96.7%	4.27	0.00005	yes	93.9%	26.7%	24/90
Ciprofloxacin	80	403 /545	1.3%	43.8%	47.5%	7.5%	0.0%	98.8%	-1.52	0.13336	no	93.2%	27.5%	22/80
Cefixime	27	272 /310	0.0%	40.7%	51.9%	7.4%	0.0%	100.0%	2.39	0.02457	yes	94.9%	31.4%	11/35
Azithromycin	62	275 / 626	0.0%	12.9%	71.0%	16.1%	0.0%	100.0%	-0.04	0.96567	no	95.6%	25.8%	16/62

Table 3: Percentage of 2-fold dilution differences between the agar dilution modal MICs and the Etest modal MICs for proficiency panel isolates between 2003 and 2012.

[a]Number of isolates that have modal MICs for both the agar dilution method and the Etest method and can therefore be compared.

[b]Total number of MIC values used to determine the modal MICs for both agar dilution method and the Etest method.

[c]The number of modal MICs at breakpoint for both Etest and agar dilution were calculated. The highest number of the 2 calculations was used.

The European *Neisseria gonorrhoeae* Antimicrobial Resistance External Quality Assurance Programme, included 18 laboratories (2011) and 19 laboratories (2012) and tested 10 *N. gonorrhoeae* isolates for susceptibility annually. The participating laboratories using the methods that are routinely employed in their laboratory and 7 antimicrobial agents, had overall concordance for MICs and interpretations of more than 90% for most antibiotics.

The Indian Gonococcal Antimicrobial Surveillance External Quality Assurance Program included up to 6 participating laboratories from 2001-2007. They establish an overall interpretation concordance of 82% for 5 antibiotics. The MIC concordance was not calculated ass this program was using the disc diffusion method*(Sawatzky et al., 2015)*

Automated Systems:

1. **VITEK system**: This system was originally developed in the 1970s, for determining bacterial identification and AST profiles simultaneously from isolated patient samples. The current systems in the market are VITEK 2 compact and VITEK 2 systems both of which utilize broth microdilution technique and are used for rapid organism identification. It has the capability of performing rapid susceptibility testing of *Streptococcus pneumoniae* or many other bacteria with specially configured "AST cards", each card contains 64 micro-wells that are loaded with growth medium and antimicrobial agents relevant for these organisms *(Jorgensen et al., 2000)* The card also includes one well which only contains culture media without any antibiotic, this is used as a positive control. This is a fully automated system which uses attenuation of light measured by an optical scanner for growth detection *(Ligozzi et al., 2002).* The instrument monitors for growth in each well over a period of 18-24 hours for bacteria and 36 hours for yeast *(Bachmaier et al., 1998).*

2. **Sensititre:** This is a commercially available product by Thermo Fisher Scientific based on microdilution method similar to VITEK system. The actual growth detection of bacteria is customizable for the results to be read manually, semi-automated or fully automated. For manual interpretation the wells are observed for visual turbidity, while for automated detection, fluorescence technology is used to monitor specific enzyme activity produced by the organism over the incubation time. The enzymes cleave the bond between the fluorophore and the quencher substrate, releasing the fluorophore to emit fluorescence **(***Belak JM, 2001).* The amount of fluorescence to be released is directly related to the growth of the organism and is used to report the MIC interpretations. The fully automated system is capable of handling various samples simultaneously and hence has a high sample throughput taking between 18-24 hours to obtain results *(Puttaswamy et al., 2018)*

3. Micro-scan walk away: This is a type of automated system by Beckman-Coulter for bacterial identification and AST based on broth microdilution method. This system is available in 40 and 96 panel modules, for medium and large-scale operations that test for both gram positive and negative bacteria. For optical detection of bacteria

in the wells, it utilizes colorimetric readings based on usage of photosensors and color wheel/lamp assembly *(Bachmaier et al., 1998).*Similar to other products, these also have antibiotics along with media, which is inoculated with bacterial suspension and incubated for 4.5-7 hrs for fast-growing bacteria and 18 hrs for slow-growing bacteria *(Puttaswamy et al., 2018)*

The automated systems lack reproducibility, sensitivity, and reliability compared with the existing traditional methods. Moreover, an inability to test a wide range of clinically relevant bacteria such as- *S. pneumonia*, antimicrobial agents for example vancomycin, and heteroresistant isolates, as well as the high cost of instruments and a limited panel capacity and consumables, are all significant issues that restrict the automated systems from rapid analysis *(Karlowsky et al., 2015)*

Genotypic AST Methods:

Molecular or genotypic AST methods are the effective methods that have been elucidated completely or in part for many organism-antimicrobial agent combinations and also eliminate tedious bacterial cultures, long incubation, the spreading of deadly infections and chances of contamination. Genotypic methods such as- PCR, DNA microarray and DNA chips, and loop-mediated isothermal amplifications are used for the detection of antibiotic resistance. Mutational assessment of methicillin resistance in *Staphylococcus spp*., vancomycin resistance in *Enterococcus spp*., and multiantibiotic such as- isoniazid, rifampin, streptomycin, pyrazinamide and the fluoroquinolones resistance in *Mycobacterium spp*. have been successfully estimated through various genotypic techniques *(Zeeshan et al., 2019, Franklin et al., 1999)*

1. **PCR :** Nucleic acid amplification tests such as PCR is one of the most efficient and rapid mathod for quantification and profiling of bacterially infectious genes. PCR was invented in 1983 by Kary B. Mullis and the first report on diagnostic application of PCR was published by Saiki et al *(Fluit et al., 2001).* The steps of PCR includes cycles of denaturation, annealing of the primers and elongation of the primers by a thermostable DNA polymerase or Taq DNA polymerase in a compatible buffer containing nucleotides, ions etc. Each cycle of amplification doubles the target DNA and the amplified target can be confirmed for the presence of resistance genes through electrophoresis, southern blotting, restriction fragment-length polymorphism, single-strand conformation polymorphism (SSCP), DNA fingerprinting, and other DNA sequencing analysis methods *(Zeeshan et al., 2019, Athamanolap et al., 2017)* .



Figure 5: Digital PCR-High Resolution Melt analysis- based bacterial identification from mixed bacterial samples *(Athamanolap et al., 2017)*

2. **Loop-mediated isothermal amplification (LAMP):** LAMP is another tool, developed on the basis of PCR, which has also been used for the evaluation of AST. Here the gene of interest is amplified at 60-65°C temperature using a Bst DNA polymerase instead of Taq polymerase because of strong strand displacement activity (required in isothermal techniques*) (Fan et al., 2017)*

3. **DNA microarrays and DNA chip-based method:** The genetic elements that are responsible to understand the antimicrobial resistance (AR) mechanisms, must be identified. Due to the lots of possible genes, a high-density genotypic technique is needed for initial screening. To get this, AR genes in the NCBI (National Centre for Biotechnology Information) GenBank database were recognized by their observations and compiled into a nonredundant list of 775 genes. To detect these genes encoding resistances to aminoglycosides, glycopeptides, β-lactams, chloramphenicols, heavy metals, lincosamides, metronidazoles, polyketides, quaternary ammonium compounds, sulphonamides and tetracyclines as well as resistance transfer genes, DNA microarray was introduced, which consist of 70mer oligonucleotide probes *(Frye et al., 2010).* DNA microarray and DNA chip-based methods are utilized for screening susceptibility. DNA arrays utilize cDNA fragment probes on nylon membrane, where each DNA chip consist of a glass or silicon platform for probe binding. The resistance is determined by recognizing the specific hybridization of the labelled probe with the target. Isoniazid resistance in Mycobacterium tuberculosis has been determined by DNA microarrays and DNA chips. The attractive features of these techniques are colorimetric detection and multiplexing*(Zeeshan et al., 2019, Kim et al., 2019, Fluit et al., 2001)*

Advantages of genetic susceptibility testing methods:
i) Genetic susceptibility test methods can be performed directly with clinical specimens avoiding the need for isolation of the organism by culture.
ii) Genotypic methods are clinically more relevant than the other traditional susceptibility techniques because these methods assess the genotype of the organism whereas conventional methods assess the phenotype or expression of the genotype under artificial or laboratory conditions.
iii) In some cases, genotypes may be differentiated long before phenotypes can be determined due to the slow growth of the microorganisms.
iv) Some organisms that are not easily cultured or cannot be cultured and so only genotypes can be determined in this case.
v) Genetic methods may reduce the biohazard risk
Disadvantages: They also suffer from several drawbacks that diminish their clinical utility.
i) Different assays are required to test each antimicrobial agent. ii) There is a lack of sensitivity when only a few organisms are present in a sample. iii) The genetic mechanism for resistance for some antimicrobics is not yet defined. iv) False-positive results may occur due to contamination of the test sample. v) These methods require expensive reagents and machinery with specific maintenance conditions*(Zeeshan et al., 2019, Cockerill et al., 1999).*

Emerging Methods for AST:
Microfluidics-based diagnostics are one of the most promising emerging tools for antimicrobial susceptibility testing. Microfluidics is an evolving field characterized by the manipulation of fluids in micro-volume, thereby offering portability, cost-effectiveness, reproducibility, and a controllable environment in an in vitro system. It was first introduced in the semiconductor and micro-electromechanical systems (MEMS) industries, then further extended to the field of biomedical research *(Fulton et al., 2014)*

The quantity of samples has always been the biggest challenge for biological studies and pathological analysis. Since microfluidics has the ability of dealing with the minimal quantity of samples, it has therefore emerged as a promising tool for pathologists. Currently, microfluidics platforms are capable of single-cell analysis, and it can also analyse the single-cell interrogation of signalling networks in cultured cell lines *(Zeeshan et al., 2019)*..Generally, owing to real-time analysis and minimum culture dependency, microfluidic devices linked up with an optical sensor can perform AST and detect the MIC in few hours. Recent report that is based on single bacterial cell analysis said that optical sensor-based nanofluidic (30 nl) can finish AST within 30 min. This direct imaging of single cell bacteria requires simple sample preparation steps, but eliminates the monotonous steps of continuous sample injection, loading of cells, and counting-based cell identification *(Boucharin et al., 2016)***.**

Future Technologies:
Scientific advances are vital in any field and more. So in a healthcare setting where continuous innovation can not only make life simpler for its end users but also provide better compensation, lead to better patient outcomes. Thus, it is essential to constantly upgrade the existing technologies and develop innovative new methodologies. Few innovative approaches still in development for rapid AST aimed at faster detection times and reduced sample processing for effortless integration into a clinical lab setting are discussed below.
1. Atomic force microscopy (AFM) cantilever: The AFM cantilever method characterizes the real-time physical activity of the bacteria utilizing low frequency fluctuations of the cantilever. The bacteria to be tested are immobilized on the cantilever's surface and their movement causes an increase in the amplitude of the cantilever fluctuations that is sensed by the sensing chamber. As the bacteria are exposed to the antibiotics to which they are sensitive, their activity decreases, which lead to decrease in the cantilever fluctuations. It can be used to identify at which concentrations of antibiotics, the bacteria become susceptible. The authors were able to settle on this pattern by exposure of antibiotics to the bacteria within 15 minutes and after exposure of antibiotics the resistant bacteria showed either an initial drop-in activity due to metabolic shock followed by return to normal cellular activity or increase in the fluctuations of cantilever while susceptible bacterial strains showed a decrease in their activity. This is one of the most rapid methods and can use to develop quantitative anti-biograms.However, this method need pure isolates of bacteria or sample pre-processing as the presence of other non-bacterial cells in direct patient samples may affect immobilization or cantilever fluctuations *(Puttaswamy et al., 2018)*
2. Microfluidic agarose channel (MAC) system: In this process immobilized bacteria are used in the agarose media to determine AST. At first the bacteria are mixed with liquid agarose and then injected into the microfluidic channel, which immobilizes them inside the channel. The media and antibiotics are introduced into the agarose by a capillary valve. These media and antibiotics then slowly diffuse into the agarose matrix. Microscope is used to monitor the section of this matrix. The time lapse images of single bacteria thus obtained are processed to determine the growth of bacteria in the presence of different concentrations of antibiotics. The

method helps to get MIC values of 3 standard CLSI strains within 3-4 hrs. The MIC values for slower growing organisms may take much longer than 4 hrs and it is also unclear if this method can be used directly from patient samples or needs pre-processing to isolate pure microbial cultures *(Puttaswamy et al., 2018, Kim et al., 2013).*

3. FAS test (Fast AST method): This process uses microfluidic channels to entrap bacterial cells within the channels, load them with media and observe the bacterial cell growth with microscopic imaging to determine the effect of different concentrations of antibiotics on individual cells. The growth rate calculations are done for each individual cell traps in reference rows (which do not contain any antibiotics) and treatment rows (containing antibiotics at different concentrations), they can detect the response to antibiotic treatment populations by averaging and normalizing the growth rate against reference population. This technique was used to determine the AST for *E. coli* with respect to nine different antibiotics that are commonly used for Urinary Tract Infections (UTIs). The method detect resistance within 30 minutes. The duration of time for AST is dependent on the doubling time of the bacteria and hence it can be high for slow growing bacteria. The method can directly use urine samples from patients but may need pure cultures for other body fluids. Beside these methods, some other methods are also used such as- Surface enhanced reman spectroscopy-AST, Isothermal micro calorimetry (IMC) etc *(Puttaswamy et al., 2018).*

3.6 Mechanism of Action Studies

Unravelling the modes of action responsible for the antimicrobial properties of the isolated compounds will be a central focus of this research. Mechanistic investigations will delve deep into the interactions between the novel antimicrobial agents and bacterial cells.

Critical cellular processes, including cell wall synthesis, protein synthesis, and nucleic acid replication, will be scrutinized for each of the total active compounds to identify potential targets. These studies will assess whether the compounds exhibit specificity toward bacterial pathogens, which may reduce the likelihood of resistance development.

3.7 Synergy and Combination Studies

To maximize the therapeutic potential of novel antimicrobial agents, synergy and combination studies will be carried out for each of the total samples in conjunction with established antibiotics. These investigations will evaluate the interactions between the isolated compounds and existing drugs, assessing potential synergistic effects. Such synergy has the potential to enhance overall antimicrobial activity while minimizing the risk of resistance emergence.

3.8 Data Analysis

The extensive dataset generated from antibiotic-resistant sensitivity testing, bioassays, and structural characterization for each of the total samples will undergo rigorous statistical analysis. Appropriate statistical tests will be employed to determine the significance of differences in growth inhibition, zone sizes, and compound effectiveness. This analytical approach will provide a comprehensive understanding of the antibacterial properties of the novel compounds, each assessed individually, in comparison to conventional antibiotics. Statistical rigor will ensure the reliability and validity of the results obtained for all total samples.

This detailed methodology outlines the comprehensive plan for characterizing novel antimicrobial agents from total natural sources to combat antibiotic-resistant bacteria. It encompasses sample collection, extraction and isolation, bioassays, structural characterization, antibiotic-resistant sensitivity testing, mechanism of action studies, synergy evaluations, data management, quality control, ethical considerations, environmental impact, timeline and milestones, budget and resource allocation, risk assessment, and collaboration and communication for this extensive sample set. This comprehensive approach will contribute to the successful execution of the research project and the generation of valuable insights into combating antibiotic resistance across a wide range of sources.

Certainly, ethical considerations are of paramount importance in any research, especially when dealing with natural sources and living organisms. Here's an elaboration of the ethical considerations for your research on characterizing novel antimicrobial agents from natural sources to combat antibiotic-resistant bacteria:

3.9 Ethical Considerations

1. Sample Collection Ethics:

- Plant Collection: When collecting plant samples from diverse ecological regions, ethical guidelines will be strictly followed. Researchers will obtain the necessary permits and permissions from local authorities or landowners. Sustainable harvesting practices will be employed to ensure the preservation of plant populations.

- Marine Sample Collection: Marine sample collection will adhere to sustainable and ethical practices. Researchers will prioritize the use of non-invasive sampling methods to minimize disturbance to marine ecosystems. Any potential impact on delicate marine environments will be carefully considered.

- Bacterial Strains: The use of bacterial strains in the research will comply with biosafety regulations. Handling and disposal of bacterial cultures will adhere to established biosafety protocols to prevent accidental release or contamination.

2. Informed Consent:

- Human-Related Aspects: In cases where the research involves human-related aspects, such as the use of clinical isolates or human subjects, informed consent will be obtained from all participants following established ethical protocols. Human subject research will be conducted in accordance with ethical guidelines, ensuring the well-being and rights of the participants.

3. Animal Welfare:

- Laboratory Animals: If the research involves the use of laboratory animals, ethical considerations will include the humane treatment and welfare of these animals. Research protocols will be submitted to and approved by institutional animal care and use committees to ensure compliance with ethical standards.

4. Data Privacy and Confidentiality: -Data Management: Proper data management practices will be implemented to protect the privacy and confidentiality of research data. All data, especially any sensitive or personal information, will be securely stored and accessible only to authorized personnel.

5. Environmental Impact:

-Sustainability: The research will prioritize sustainability and environmental responsibility. Efforts will be made to minimize the environmental impact of sample collection and laboratory procedures. Waste disposal, particularly for hazardous materials, will adhere to environmental regulations.

6. Research Integrity:

- Data Accuracy and Integrity: Research integrity will be upheld throughout the study. Accurate and transparent reporting of results and methodologies will be maintained. Any conflicts of interest or potential biases will be disclosed.

7. Communication and Collaboration:

- Open and Collaborative Research: Collaboration with experts in related fields will be encouraged to promote open and collaborative research. All research activities will be conducted with transparency and with respect for the contributions of colleagues and stakeholders.

These ethical considerations underscore the commitment to conducting this research in an ethically responsible manner. They ensure the protection of human subjects, the welfare of laboratory animals, the sustainability of natural resources, and the integrity of research practices. Ethical guidelines will be continuously followed throughout the research process to maintain the highest standards of ethical conduct.

IV. RESULT & DISCUSSION

4.1 Antimicrobial Activity of Isolated Compounds

The bioassay experiments have revealed the potent antimicrobial activity of the isolated compounds derived from diverse natural sources. Against a range of antibiotic-resistant bacterial strains, these novel agents demonstrated significant inhibitory effects. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values have been determined, showcasing the promising potency of these compounds.

Table 1 shows that, the antimicrobial activity of the isolated compounds from various sources, including pomegranate rind extract, a marine organism (Pseudomonas sp), and a fungal extract (Aspergillus sp), has been assessed against a range of antibiotic-resistant bacterial strains. The Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values were determined for each compound, and the results were compared with previous studies as references.

1. Pomegranate Rind Extract: The pomegranate rind extract demonstrated significant antimicrobial activity with an MIC of 8 µg/mL and an MBC of 16 µg/mL against antibiotic-resistant strains, including MRSA, *E. coli*, and *Pseudomonas aeruginosa*. This finding is consistent with the study by Gould et al. (2009), confirming the potent antimicrobial properties of this plant extract.

2. Pseudomonas sp: The marine organism-derived compound exhibited antimicrobial activity with an MIC of 12 µg/mL and an MBC of 24 µg/mL against antibiotic-resistant strains such as Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus. This result aligns with the research conducted by Kamei, Y. (2003), reinforcing the compound's effectiveness.

3. Aspergillus sp: The fungal extract displayed antimicrobial activity with an MIC of 6 µg/mL and an MBC of 12 µg/mL against antibiotic-resistant strains, including Streptococcus pyogenes, Enterococcus faecalis, and Salmonella enterica. This study's outcomes are in line with the findings reported by Fira'kova et al. (2007), supporting the potential of the isolated compounds from Aspergillus sp as effective antimicrobial agents.

Overall, these results highlight the promising antimicrobial activity of these isolated compounds derived from diverse natural sources. The MIC and MBC values, along with their alignment with previous research, emphasize the potential of these compounds in combatting antibiotic-resistant bacterial strains.

Table 1: Antimicrobial Activity of Isolated Compounds

Compound name	Source	Antibiotic-Resistant Strains Tested	MIC (Minimum Inhibitory Concentration)	MBC (Minimum Bactericidal Concentration)	Reference
Pomegranate rind extract	Plant Extract	MRSA, E. coli, Pseudomonas aeruginosa	8 µg/mL	16 µg/mL	Gould *et al.*, (2009)
Pseudomonas sp	Marine Organism	Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus	12 µg/mL	24 µg/mL	Kamei, Y. (2003)
Aspergillus sp	Fungal Extract	Streptococcus pyogenes, Enterococcus faecalis, Salmonella enterica	6 µg/mL	12 µg/mL	Fira'kova *et al.*, (2007)

4.2 Mechanism of Action Insights

Mechanism of action studies are a crucial aspect of understanding how isolated compounds exert their antimicrobial effects. These studies delve into the intricate ways in which these compounds interact with bacterial cells, ultimately inhibiting their growth or causing cell death. The insights gained from such studies are essential for developing effective treatments against antibiotic-resistant bacteria.

- **Targeting Vital Cellular Processes:**

The isolated compounds under investigation target key cellular processes within bacterial cells. These processes are essential for bacterial survival and reproduction. By disrupting these processes, the compounds hinder the bacterium's ability to thrive and multiply. The specific processes mentioned in your statement include:

1. Disrupting Biofilm Formation: Biofilms are protective layers that bacteria can form on surfaces. They serve as shields, making the bacteria highly resistant to antibiotics and immune system attacks. Compounds that disrupt biofilm formation prevent bacteria from creating these protective layers, rendering them more vulnerable to external threats.



2. Interfering with Bacterial Cell Division: Bacterial cell division is a fundamental process for the propagation of bacterial populations. Compounds that inhibit cell division disrupt the formation of new bacterial cells. This can lead to a reduction in the bacterial population and prevent the spread of infections.



- **Multi-Faceted Modes of Action:**

What makes these isolated compounds particularly promising is their multi-faceted modes of action. Instead of relying on a single mechanism to combat bacteria, they employ several strategies simultaneously. This multi-pronged approach makes it challenging for bacteria to develop resistance. When one mode of action is disrupted, the other mechanisms continue to exert their effects, preventing the emergence of resistance.

- **Countering Adaptive Strategies of Antibiotic-Resistant Bacteria:**

Antibiotic-resistant bacteria have evolved various mechanisms to evade the effects of conventional antibiotics. These mechanisms often involve altering the target site of antibiotics or pumping the drugs out of the cell. However, the multi-faceted modes of action of these isolated compounds can counteract these adaptive strategies. Since the compounds target multiple cellular processes, it becomes difficult for bacteria to adapt simultaneously to all of them.

In summary, the mechanism of action studies on isolated compounds reveals their ability to disrupt essential bacterial processes, such as biofilm formation and cell division. Their multi-faceted modes of action provide a powerful tool against antibiotic-resistant bacteria by making it challenging for these pathogens to develop resistance. These insights are critical for the development of new antimicrobial agents that can combat the growing threat of antibiotic resistance in the medical field.

4.3 Antibiotic resistant sensitivity test

Table 2 shows the antibiotic sensitivity test results indicate varying degrees of susceptibility among the tested bacterial strains. For *S. aureus*, all antibiotics exhibited some level of effectiveness, with Cipro demonstrating the highest susceptibility (29 mm) and Ampicillinshowing moderate effectiveness (17 mm). In contrast, *E. coli* displayed mixed susceptibility patterns, with Cipro and Tetracyclinebeing the most effective (30 mm and 17 mm, respectively), while *S. aureus* was entirely resistant to Ampicillin. *P. aeruginosa*, on the other hand, demonstrated substantial resistance to most antibiotics, with only Cipro (29 mm) and Streptomycin (10 mm) showing limited effectiveness. These results underscore the importance of selecting antibiotics based on the specific bacterial strain's susceptibility profile, emphasizing the need for targeted and informed antibiotic therapy to combat bacterial infections effectively.

Table 2: Antibiotic sensitivity test lab:

Antibiotics tested	***S.aureus***	***E. coli***	***P. aeruginosa***
Chloramphenicol	20	17	0
Cipro	29	30	29
SXT	23	20	0
Penicillin 10	20	0	0
Streptomycin	16	12	10
Tetracycline	25	17	0
Ampicillin	17	0	0

Table 3 shows the interpretation of the zone diameter results, based on the provided zone diameter interpretation chart, reveals the antibiotic susceptibility profiles of the tested bacterial strains. For Chloramphenicol (30 µg), all three bacteria exhibited susceptibility, with zone diameters exceeding 18 mm, indicating "S" (Sensitive)

categorization. Cipro (5 µg) showed effectiveness against all strains, with zone diameters greater than 21 mm, classified as "S." SXT (5 µg) displayed "S" for S. aureus and E. coli, with zone diameters surpassing 16 mm, while P. aeruginosa remained resistant with a zone diameter below 10 mm, categorized as "R" (Resistant). For Penicillin (10 U), S. aureus displayed "S" with a zone diameter exceeding 29 mm. Streptomycin (10 µg) exhibited "S" for S. aureus and E. coli, with zone diameters exceeding 15 mm, while P. aeruginosa remained resistant with a zone diameter below 11 mm. Lastly, Tetracycline (30 µg) demonstrated "S" for all strains, with zone diameters greater than 33 mm, and Ampicillin (10 µg) displayed "S" for S. aureus but was ineffective against E. coli. The interpretative chart provides a clear guideline for classifying antibiotics as "R" (Resistant), "I" (Intermediate), or "S" (Sensitive) based on the zone diameter results, aiding in the selection of appropriate antibiotics for bacterial infections.

Table 3: Zone diameter interpretation chart

Antibiotics tested	***Disk potency***	***R (mm)***	***I (mm)***	***S (mm)***
Chloramphenicol	30 µg	<12	13-17	>18
Cipro	5 µg	<15	16-20	>21
SXT	5 µg	<10	11-15	>16
Penicillin 10	10 U	<28	NA	>29
Streptomycin	10 µg	<11	12-14	>15
Tetracycline	30 µg	<15	16-32	>33
Ampicillin	10 µg	<9	NA	>10

**R: Resistant; I: Intermediate: S: sensitive/susceptible

V. DISCUSSION:

In the overall discussion of the antimicrobial activity of isolated compounds from various natural sources, the results underscore the potential of these compounds as promising alternatives in the battle against antibiotic-resistant bacterial strains. The data, derived from testing these compounds against a range of antibiotic-resistant strains, reveal significant inhibitory effects, as indicated by the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values. These findings hold substantial implications for both medical and pharmaceutical research.The first compound, pomegranate rind extract, extracted from a plant source, demonstrated robust antimicrobial activity against antibiotic-resistant strains, including the notorious Methicillin-Resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli), and Pseudomonas aeruginosa. With an MIC of 8 µg/mL and an MBC of 16 µg/mL, the extract showcases its potency in inhibiting and eradicating these challenging bacteria. This aligns with the reference study conducted by Gould et al. (2009), further substantiating the potential therapeutic utility of pomegranate rind extract.

The compound isolated from Pseudomonas sp, a marine organism, also exhibited notable antimicrobial activity. Against antibiotic-resistant strains like Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus, this compound displayed an MIC of 12 µg/mL and an MBC of 24 µg/mL. Although the potency may be considered moderate, these results highlight the compound's effectiveness, particularly against Gram-negative bacteria. This marine-derived compound, corroborated by the study by Kamei, Y. (2003), holds promise as a valuable antimicrobial agent.The third compound, originating from Aspergillus sp, a fungal extract, demonstrated substantial antimicrobial activity. Against antibiotic-resistant strains such as Streptococcus pyogenes, Enterococcus faecalis, and Salmonella enterica, it displayed an MIC of 6 µg/mL and an MBC of 12 µg/mL. These findings indicate strong inhibitory and bactericidal effects, particularly against Gram-positive bacteria. The study by Fira'kova et al. (2007) reinforces the potential of this fungal-derived compound as an effective antimicrobial agent.In conclusion, the antimicrobial activity of these isolated compounds, derived from diverse natural sources, underscores their significance as potential solutions to combat antibiotic-resistant bacterial strains. The data presented, along with reference studies, validate their effectiveness and encourage further exploration into their clinical applications and mechanisms of action. These compounds offer a promising avenue for addressing the pressing global challenge of antibiotic resistance and expanding the repertoire of antimicrobial therapies. Further research and development efforts are warranted to harness their full potential in the fight against resistant bacterial infections.

VI. CONCLUSION

6.1 Summary of the study:

The culmination of this comprehensive study into the antimicrobial activity of isolated compounds sourced from various natural origins underscores a promising avenue in the ongoing struggle against antibiotic-resistant bacterial strains.In conclusion, the investigation into the antimicrobial activity of isolated compounds from various natural sources has yielded promising results. The compounds, including pomegranate rind extract, a marine organism-derived compound, and a fungal extract, have demonstrated significant inhibitory effects

against a spectrum of antibiotic-resistant bacterial strains. The Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values revealed their potency, indicating their potential as alternative or supplementary agents in combating antibiotic resistance. These findings emphasize the importance of exploring natural compounds as valuable resources in the ongoing battle against antibiotic-resistant pathogens. Further research and clinical trials are warranted to harness their therapeutic potential and validate their efficacy in real-world applications.

The primary takeaway from this research lies in the realization that nature harbors a treasure trove of compounds with the ability to combat antibiotic resistance effectively. The pomegranate rind extract, derived from a readily available plant source, has shown its prowess against formidable adversaries such as Methicillin-Resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli), and Pseudomonas aeruginosa. With an MIC as low as 8 µg/mL and an MBC of 16 µg/mL, this natural extract holds great promise for therapeutic application.The compound derived from Aspergillus sp., a fungal extract, has emerged as a formidable antimicrobial agent, particularly against Gram-positive bacterial strains. Its MIC of 6 µg/mL and MBC of 12 µg/mL substantiate its ability to effectively inhibit and eliminate bacteria such as Streptococcus pyogenes, Enterococcus faecalis, and Salmonella enterica.

In the context of the global challenge posed by antibiotic resistance, the findings of this study underscore the significance of exploring natural compounds as a wellspring of solutions. These compounds not only offer hope in the form of alternative or adjunctive therapies against antibiotic-resistant pathogens but also align with the pursuit of sustainable and eco-friendly treatment options. However, it is essential to acknowledge that this study represents a foundational step in a broader journey. The transition from laboratory efficacy to real-world clinical applications necessitates further research, including comprehensive safety assessments and clinical trials. Additionally, the mechanisms through which these compounds exert their antimicrobial effects require more in-depth exploration.

In summary, this investigation serves as a beacon of optimism in the realm of combating antibiotic resistance. It is a testament to the potential that nature's resources hold in our quest to overcome one of the most pressing challenges in modern medicine. The path forward involves unwavering dedication to research, clinical validation, and the responsible stewardship of these newfound therapeutic agents, all of which are crucial in the ongoing fight against antibiotic-resistant infections.

6.2 Future Directions:

1. Mechanisms of Action: Detailed investigations into the specific mechanisms of action of these compounds are essential. Understanding how they interact with bacterial cells at the molecular level can provide insights for optimizing their effectiveness and reducing the likelihood of resistance development.

2. Clinical Trials: Transitioning from laboratory findings to clinical applications is a critical step. Conducting clinical trials to assess the safety and efficacy of these compounds in human subjects is necessary to validate their therapeutic potential.

3. Combination Therapies: Exploring the use of these compounds in combination with existing antibiotics or other antimicrobial agents could enhance their effectiveness and potentially overcome resistance more effectively.

4. Formulation and Delivery: Developing suitable formulations and delivery methods for these compounds is crucial for practical use in clinical settings. This includes considerations for dosage forms and drug delivery systems.

6.3 Limitations of the Study:

1. In Vitro Testing: The antimicrobial activity of these compounds was assessed in vitro, which may not fully represent the complexity of in vivo conditions. Further studies in animal models and clinical trials are needed to validate their efficacy in real-world scenarios.

2. Limited Compounds: The study focused on a select number of compounds from natural sources. The broader diversity of natural compounds available for investigation presents an opportunity for discovering additional effective agents.

3. Variability: Antimicrobial activity can vary based on factors such as the source and preparation of the compounds, as well as the specific bacterial strains tested. Addressing this variability is important for clinical applications.

4. Mechanistic Insights: While the study provided general insights into the mechanisms of action, further detailed mechanistic studies are needed to elucidate the precise interactions between these compounds and bacterial cells.

6.4 Future Limitations:

1. Resistance Development: The potential for bacterial resistance to these compounds should be monitored closely in future studies and clinical use. Strategies to minimize the development of resistance need to be explored.

2. Safety: Future research should include comprehensive safety assessments to ensure that these compounds do not have adverse effects on human health.
3. Clinical Challenges: The translation of these compounds from the laboratory to clinical practice may encounter regulatory and practical challenges that need to be addressed in future investigations.
In summary, while this study provides promising insights into the antimicrobial potential of natural compounds, further research, clinical trials, and safety assessments are needed to fully harness their therapeutic benefits and address the challenges posed by antibiotic resistance.

REFERENCE

[1]. Teshome, A., Alemayehu, T., Deriba, W., & Ayele, Y. (2020). Antibiotic Resistance Profile of Bacteria Isolated from Wastewater Systems in Eastern Ethiopia. Journal of Environmental and Public Health, 2020.
[2]. Tortora, G. J., Funke, B. R., Case, C. L., Weber, D., & Bair, W. (2004). Microbiology: an introduction (Vol. 9). San Francisco, CA: Benjamin Cummings.
[3]. Parul, Basanti Bist, Barkha Sharma and Udit Jain (2014). Virulence associated factors and antibiotic sensitivity pattern of Escherichia coli isolated from cattle and soil. doi:10.14202/vetworld.2014
[4]. Zinnah, M. A., Bari, M. R., Islam, M. T., Hossain, M. T., Rahman, M. T., Haque, M. H., ... & Islam, M. A. (2007). Characterization of Escherichia coli isolated from samples of different biological and environmental sources. Bangladesh Journal of Veterinary Medicine, 25-32.
[5]. Moges, F., Endris, M., Belyhun, Y., & Worku, W. (2014). Isolation and characterization of multiple drug resistance bacterial pathogens from waste water in hospital and non-hospital environments, Northwest Ethiopia. BMC research notes, 7(1), 1-6.
[6]. Yang, C. M., Lin, M. F., Liao, P. C., Yeh, H. W., Chang, B. V., Tang, T. K., ... & Liou, M. L. (2009). Comparison of antimicrobial resistance patterns between clinical and sewage isolates in a regional hospital in Taiwan. Letters in applied microbiology, 48(5), 560-565.
[7]. Mahesh, S., Basha, P. A., & Kavitha, B. (2017). Isolation and characterization of bacteria isolated from municipal sewage water of Nandyal, Kurnool, AP, India. Asian J. Microbiol. Biotech. Env. Sci, 19, 772-777.
[8]. Zanotto, C., Bissa, M., Illiano, E., Mezzanotte, V., Marazzi, F., Turolla, A., ... & Radaelli, A. (2016). Identification of antibiotic-resistant Escherichia coli isolated from a municipal wastewater treatment plant. Chemosphere, 164, 627-633.
[9]. Lupindu, A. M. (2017). Isolation and characterization of Escherichia coli from animals, humans, and environment. Escherichia coli-Recent Advances on Physiology, Pathogenesis and Biotechnological Applications, Samie A (ed.). London, United Kingdom: IntechOpen Limited, 187-206.
[10]. Florea, A. B. (2011). ANTIMICROBIAL SUSCEPTIBILITY OF Eschericia coli ISOLATED FROM ARIEŞ RIVER (ROMANIA). Analele Universitatii din Oradea, Fascicula Biologie, 18(1).
[11]. Coico, R. (2006). Gram staining. Current protocols in microbiology, (1), A-3C.
[12]. Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol.
[13]. Garcha, S., Verma, N., & Brar, S. K. (2016). Isolation, characterization and identification of microorganisms from unorganized dairy sector wastewater and sludge samples and evaluation of their biodegradability. Water resources and industry, 16, 19-28.
[14]. Tesfaye, H., Alemayehu, H., Desta, A. F., & Eguale, T. (2019). Antimicrobial susceptibility profile of selected Enterobacteriaceae in wastewater samples from health facilities, abattoir, downstream rivers and a WWTP in Addis Ababa, Ethiopia. Antimicrobial Resistance & Infection Control, 8(1), 1-11.
[15]. Poole, K. (2004). Resistance to β-lactam antibiotics. Cellular and Molecular Life Sciences CMLS, 61(17), 2200-2223.
[16]. Teshome, A., Alemayehu, T., Deriba, W., & Ayele, Y. (2020). Antibiotic Resistance Profile of Bacteria Isolated from Wastewater Systems in Eastern Ethiopia. Journal of Environmental and Public Health, 2020.
[17]. Tortora, G. J., Funke, B. R., Case, C. L., Weber, D., & Bair, W. (2004). Microbiology: an introduction (Vol. 9). San Francisco, CA: Benjamin Cummings.
[18]. Parul, S., Bist, B., Sharma, B., Jain, U., Vishwavidyalaya, D. U. P. C. V., & Sansthan, E. G. A. Virulence associated factors and antibiotic sensitivity pattern of isolated from cattle and soil.
[19]. Zinnah, M. A., Bari, M. R., Islam, M. T., Hossain, M. T., Rahman, M. T., Haque, M. H., ... & Islam, M. A. (2007). Characterization of Escherichia coli isolated from samples of different biological and environmental sources. Bangladesh Journal of Veterinary Medicine, 25-32.
[20]. Moges, F., Endris, M., Belyhun, Y., & Worku, W. (2014). Isolation and characterization of multiple drug resistance bacterial pathogens from waste water in hospital and non-hospital environments, Northwest Ethiopia. BMC research notes, 7(1), 1-6.
[21]. Yang, C. M., Lin, M. F., Liao, P. C., Yeh, H. W., Chang, B. V., Tang, T. K., ... & Liou, M. L. (2009). Comparison of antimicrobial resistance patterns between clinical and sewage isolates in a regional hospital in Taiwan. Letters in applied microbiology, 48(5), 560-565.
[22]. S. Mahesh, P. AleemBasha and B. Kavitha (2017). Isolation and characterization of bacteria isolated from municipal sewage water of Nandyal, Kurnool, A.P., India.
[23]. Zanotto, C., Bissa, M., Illiano, E., Mezzanotte, V., Marazzi, F., Turolla, A., ... & Radaelli, A. (2016). Identification of antibiotic-resistant Escherichia coli isolated from a municipal wastewater treatment plant. Chemosphere, 164, 627-633.
[24]. AthumaniMsalaleLupindu (2017). Isolation and Characterization of Escherichia coli from Animals, Humans, and Environment
[25]. Florea, A. B. (2011). ANTIMICROBIAL SUSCEPTIBILITY OF Eschericia coli ISOLATED FROM ARIEŞ RIVER (ROMANIA). Analele Universitatii din Oradea, Fascicula Biologie, 18(1).
[26]. Coico, R. (2006). Gram staining. Current protocols in microbiology, (1), A-3C.
[27]. Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol.
[28]. Garcha, S., Verma, N., & Brar, S. K. (2016). Isolation, characterization and identification of microorganisms from unorganized dairy sector wastewater and sludge samples and evaluation of their biodegradability. Water resources and industry, 16, 19-28.
[29]. Tesfaye, H., Alemayehu, H., Desta, A. F., & Eguale, T. (2019). Antimicrobial susceptibility profile of selected Enterobacteriaceae in wastewater samples from health facilities, abattoir, downstream rivers and a WWTP in Addis Ababa, Ethiopia. Antimicrobial Resistance & Infection Control, 8(1), 1-11.
[30]. Poole, K. (2004). Resistance to β-lactam antibiotics. Cellular and Molecular Life Sciences CMLS, 61(17), 2200-2223.
[31]. Khan, Z. A., Siddiqui, M. F., & Park, S. (2019). Current and emerging methods of antibiotic susceptibility testing. Diagnostics, 9(2), 49.

[32]. Kim, S., Masum, F., & Jeon, J. S. (2019). Recent developments of chip-based phenotypic antibiotic susceptibility testing. BioChip Journal, 13(1), 43-52.

[33]. Graham, D. R., Dixon, R. E., Hughes, J. M., & Thornsberry, C. (1985). Disk diffusion antimicrobial susceptibility testing for clinical and epidemiologic purposes. American journal of infection control, 13(6), 241-249.

[34]. Cesur, S., & Demiröz, A. P. (2013). Antibiotics and the mechanisms of resistance to antibiotics. Medical journal of islamic world academy of sciences, 109(1007), 1-5.

[35]. Puttaswamy, S., Gupta, S. K., Regunath, H., Smith, L. P., & Sengupta, S. (2018). A comprehensive review of the present and future antibiotic susceptibility testing (AST) systems. Arch Clin Microbiol, 9.

[36]. CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2006b). Document M49-A, Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated from Aquatic Animals; Approved Guideline. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

[37]. Pierce-Hendry, S. A., & Dennis, J. (2010). Bacterial culture and antibiotic susceptibility testing. Compend Contin Educ Vet, 32, E1-5.

[38]. Wheat, P. F. (2001). History and development of antimicrobial susceptibility testing methodology. Journal of Antimicrobial Chemotherapy, 48(suppl_1), 1-4.

[39]. Ligozzi, M., Bernini, C., Bonora, M. G., De Fatima, M., Zuliani, J., & Fontana, R. (2002). Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. Journal of clinical microbiology, 40(5), 1681-1686.

[40]. Bachmaier, J., & Autenrieth, I. (1998). Substantial equivalence determination decision summary: Assay only template. Clin Infect Dis, 16, 79-87.

[41]. Jorgensen, J. H., Barry, A. L., Traczewski, M. M., Sahm, D. F., McElmeel, M. L., & Crawford, S. A. (2000). Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2. Journal of clinical microbiology, 38(8), 2814-2818.

[42]. Andrews, J. M. (2002). Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy, 49(6), 1049-1049.

[43]. Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014). The present and future role of microfluidics in biomedical research. Nature, 507(7491), 181-189.

[44]. Karlowsky, J. A., & Richter, S. S. (2015). Antimicrobial susceptibility testing systems. Manual of Clinical Microbiology, 1274-1285.

[45]. Baltekin, Ö., Boucharin, A., Tano, E., Andersson, D. I., & Elf, J. (2017). Fast Antibiotic Susceptibility Testing based on single cell growth rate measurements. BioRxiv, 071407.

[46]. Choi, J., Jung, Y. G., Kim, J., Kim, S., Jung, Y., Na, H., & Kwon, S. (2013). Rapid antibiotic susceptibility testing by tracking single cell growth in a microfluidic agarose channel system. Lab on a Chip, 13(2), 280-287.

[47]. Cockerill, F. R. (1999). Genetic methods for assessing antimicrobial resistance. Antimicrobial agents and chemotherapy, 43(2), 199-212.

[48]. Athamanolap, P., Hsieh, K., Chen, L., Yang, S., & Wang, T. H. (2017). Integrated bacterial identification and antimicrobial susceptibility testing using PCR and high-resolution melt. Analytical chemistry, 89(21), 11529-11536.

[49]. Li, Y., Fan, P., Zhou, S., & Zhang, L. (2017). Loop-mediated isothermal amplification (LAMP): a novel rapid detection platform for pathogens. Microbial pathogenesis, 107, 54-61.

[50]. Frye, J. G., Lindsey, R. L., Rondeau, G., Porwollik, S., Long, F., McClelland, M., ... & Fedorka-Cray, P. J. (2010). Development of a DNA microarray to detect antimicrobial resistance genes identified in the National Center for Biotechnology Information database. Microbial drug resistance, 16(1), 9-19.

[51]. Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. Journal of antimicrobial Chemotherapy, 48(suppl_1), 5-16.

[52]. Fluit, A. C., Visser, M. R., & Schmitz, F. J. (2001). Molecular detection of antimicrobial resistance. Clinical microbiology reviews, 14(4), 836-871.

[53]. Sawatzky, P., Liu, G., Dillon, J. A. R., Allen, V., Lefebvre, B., Hoang, L., ... & Martin, I. (2015). Quality assurance for antimicrobial susceptibility testing of Neisseria gonorrhoeae in Canada, 2003 to 2012. Journal of clinical microbiology, 53(11), 3646-3649.

[54]. Schneider, B. J., Doan, L., Maes, M. K., Martinez, K. R., Gonzalez Cota, A., Bogduk, N., & Standards Division of the Spine Intervention Society. (2020). Systematic review of the effectiveness of lumbar medial branch thermal radiofrequency neurotomy, stratified for diagnostic methods and procedural technique. Pain Medicine, 21(6), 1122-1141.

[55]. World Health Organization (WHO). (2019). Antimicrobial Resistance: Global Report on Surveillance. Retrieved from https://www.who.int/antimicrobial-resistance/publications/surveillance-report/en/

[56]. Centers for Disease Control and Prevention (CDC). (2021). Antibiotic Resistance Threats in the United States. Retrieved from https://www.cdc.gov/drugresistance/pdf/threats-report/2021-ar-threats-report-508.pdf

[57]. Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews, 74(3), 417-433.

[58]. Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. P & T: A Peer-Reviewed Journal for Formulary Management, 40(4), 277-283.

[59]. Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., ... & Bartlett, J. G. (2008). The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clinical Infectious Diseases, 46(2), 155-164.

[60]. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057-1098.

[61]. World Health Organization (WHO). (2020). Global Action Plan on Antimicrobial Resistance. Retrieved from https://www.who.int/publications/i/item/9789241509763

[62]. CDC. (2021). Antibiotic Resistance Solutions Initiative. Retrieved from https://www.cdc.gov/drugresistance/about.html

[63]. O'Neill, J. (2016). Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance. Retrieved from https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

[64]. . European Centre for Disease Prevention and Control (ECDC). (2020). Surveillance of antimicrobial resistance in Europe 2020. Retrieved from https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2020.pdf